Avidity Biosciences, Inc. — Director's Dealing 2020

Jun 12, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2020-06-11

Reporting Person: WILSON TROY EDWARD (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	189618	Direct
Common Stock	616259	Indirect
Common Stock	35553	Indirect
Common Stock	35553	Indirect
Common Stock	11851	Indirect
Common Stock	11851	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$0.00		Common Stock (120837)		Indirect
Series B Preferred Stock	$0.00		Common Stock (16769)		Indirect
Series C Preferred Stock	$0.00		Common Stock (51436)		Indirect

Footnotes

F1: Includes 59,256 shares subject to repurchase by the Issuer, which shares will vest in 15 equal monthly installments beginning on June 29, 2020.

F2: The 254,907 shares of Series A Preferred Stock, 35,374 shares of Series B Preferred Stock and 108,504 shares of Series C Preferred Stock are convertible at any time, at the holder's election, at a ratio of one-for-2.1095 shares of the Issuer's common stock, and have no expiration date. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of preferred stock will automatically convert at a ratio of one-for-2.1095 shares of the Issuer's common stock.